...
首页> 外文期刊>Surgery >Apoptosis regulating genes, bcl-2 and bax, and human telomerase reverse transcriptase messenger RNA expression in adrenal tumors: possible diagnostic and prognostic importance.
【24h】

Apoptosis regulating genes, bcl-2 and bax, and human telomerase reverse transcriptase messenger RNA expression in adrenal tumors: possible diagnostic and prognostic importance.

机译:肾上腺肿瘤中凋亡调节基因bcl-2和bax以及人类端粒酶逆转录酶信使RNA的表达:可能的诊断和预后重要性。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

BACKGROUND: Apoptosis-suppressing gene, bcl-2, and apoptosis-inducing gene, bax, are expressed in various tumors. Human telomerase reverse transcriptase (hTERT) expression is increased in many cancers. The purpose of this investigation was to determine whether bcl-2 or bax gene expression differs between benign and malignant adrenal tumors, and whether hTERT gene expression correlates with the prognosis of patients with adrenal cancer. METHODS: Expression of bcl-2 and bax from 52 adrenal surgical specimens was analyzed by reverse transcription-polymerase chain reaction. Expression of hTERT was analyzed by real-time quantitative reverse transcription-polymerase chain reaction, and expressed using the delta-delta threshold cycle method. RESULTS: All normal adrenal tissues (n = 7) and benign adrenal tumors (n = 41) expressed bcl-2 and bax, whereas all adrenocortical cancers (n = 4) expressed bcl-2 but not bax. Expression of hTERT was increased in adrenocortical cancers compared with that in normal tissues(P <.05), cortical adenomas (n = 17) (P <.05), cortical hyperplasias (n = 4) (P <.05), and pheochromocytomas (n = 20) (P <.05). The one patient with an adrenocortical cancer without increased hTERT expression is alive with distant metastasis 5 years after adrenalectomy. The other 3 patients with adrenocortical cancer died 5 to 24 months after adrenalectomy. CONCLUSIONS: Expression of bax gene appears to distinguish adrenal cancer from benign adrenal tumors. Gene expression of hTERT should be investigated as a prognostic marker in adrenal cortical cancers.
机译:背景:凋亡抑制基因bcl-2和凋亡诱导基因bax在各种肿瘤中都有表达。在许多癌症中,人类端粒酶逆转录酶(hTERT)表达增加。这项研究的目的是确定良性和恶性肾上腺肿瘤之间bcl-2或bax基因表达是否不同,以及hTERT基因表达是否与肾上腺癌患者的预后相关。方法:采用逆转录-聚合酶链反应分析52例肾上腺手术标本中bcl-2和bax的表达。通过实时定量逆转录-聚合酶链反应分析hTERT的表达,并使用delta-delta阈值循环法进行表达。结果:所有正常肾上腺组织(n = 7)和良性肾上腺肿瘤(n = 41)均表达bcl-2和bax,而所有肾上腺皮质癌(n = 4)均表达bcl-2但不表达bax。与正常组织相比,肾上腺皮质癌中hTERT的表达增加(P <.05),皮质腺瘤(n = 17)(P <.05),皮质增生(n = 4)(P <.05)和嗜铬细胞瘤(n = 20)(P <.05)。一名肾上腺皮质癌患者,hTERT表达没有增加,但活着并在肾上腺切除术后5年发生了远处转移。另外3名肾上腺皮质癌患者在肾上腺切除术后5至24个月死亡。结论:bax基因的表达似乎可以区分肾上腺癌和良性肾上腺肿瘤。 hTERT的基因表达应作为肾上腺皮质癌的预后指标进行研究。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号